SRES 464 Passed Senate Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
A resolution designating September 2025 as "National Cholesterol Education Month" and September 30, 2025, as "LDL-C Awareness Day".
Designating September 2025 as ``National Cholesterol Education Month'' and September 30, 2025, as ``LDL-C Awareness Day''.
Summary
- Designates September 2025 as "National Cholesterol Education Month"
- Designates September 30, 2025, as "LDL-C Awareness Day"
- Encourages all individuals in the United States to know their LDL-C (low density lipoprotein cholesterol) number
- Recognizes the urgent need for screening and treating elevated LDL-C to reduce the risk of cardiovascular disease, heart attacks, and strokes
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
-
Sen. Hyde-Smith, Cindy (R-MS)
5 cosponsors
-
Sen. Boozman, John (R-AR) -
Sen. Daines, Steve (R-MT) -
Sen. Marshall, Roger (R-KS) -
Sen. Padilla, Alex (D-CA) -
Sen. Peters, Gary C. (D-MI)
Money behind the sponsor
Top reported contributors to Cindy Hyde-Smith’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- Employer not reported $81,880
- SEEMANN COMPOSITES $20,300
- BGR GROUP $7,500
- HORNE $6,871
- HOUSEWIFE $6,600
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Cindy Hyde-Smith → · Outside spending →
Actions (3)
- Oct 23, 2025 Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S7735; text: CR S7732-7733) · senate
- Oct 23, 2025 Passed/agreed to in Senate: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent.
- Oct 23, 2025 Introduced in Senate
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE SENATE OF THE UNITED STATES
October 23, 2025
Mrs. Hyde-Smith (for herself, Mr. Peters, Mr. Boozman, Mr. Marshall, Mr. Daines, and Mr. Padilla) submitted the following resolution; which was considered and agreed to
RESOLUTION
Designating September 2025 as “National Cholesterol Education Month” and September 30, 2025, as “LDL-C Awareness Day”.
Whereas cardiovascular disease is the leading cause of death for men and women in the United States; Whereas projected rates of cardiovascular disease are expected to increase significantly in the United States by 2060; Whereas, compared to urban areas, rural areas in the United States have higher death rates for cardiovascular disease and stroke, and a 40 percent higher prevalence of cardiovascular disease; Whereas risk factors contributing to cardiovascular disease and poor health outcomes include elevated low density lipoprotein cholesterol (referred to in this preamble as “LDL-C”), high levels of lipoprotein(a) cholesterol, hypertension, obesity, low awareness of personal risk factors, genetics, geographic location, and inequitable access to care; Whereas lipoprotein(a) cholesterol is predominantly genetically inherited and can build up in the walls of blood vessels, creating cholesterol deposits, or plaques, and lead to atherosclerotic cardiovascular disease; Whereas LDL-C is a modifiable risk factor for cardiovascular disease, and having lower LDL-C is associated with a reduced risk of heart attack and stroke; Whereas more than 25.5 percent of adults in the United States have high LDL-C; Whereas more than 200 studies with more than 2,000,000 patients have broadly established that elevated LDL-C causes atherosclerotic cardiovascular disease; Whereas atherosclerotic cardiovascular disease is the build-up of cholesterol plaque within the walls of arteries and includes acute coronary syndrome, peripheral arterial disease, and events such as heart attacks and strokes; Whereas the resources needed to bend the curve on cardiovascular disease exist, yet 71 percent of hypercholesterolemia patients at high risk of a cardiovascular event never achieve recommended LDL-C treatment guideline thresholds; Whereas only 33 percent of individuals with atherosclerotic cardiovascular disease who are taking statins, a guideline recommended lipid-lowering therapy, actually achieve LDL-C goals; Whereas, although clinical guidelines recommend that a patient hospitalized for heart attack receive an LDL-C test in the 90 days following discharge from a hospital, only 27 percent of patients receive the test; Whereas African-American adults are less likely to receive an LDL-C test in the 90 days following discharge from a hospital, despite having a higher prevalence of cardiovascular disease; Whereas significant gaps in care may lead to subsequent cardiovascular events; Whereas the Million Hearts program seeks to improve access to and quality of care to reduce heart disease, stroke, and death; and Whereas September is recognized as National Cholesterol Education Month to raise awareness of cardiovascular disease and the importance of individuals knowing their LDL-C number: Now, therefore, be it Resolved, That the Senate—
(1) encourages all individuals in the United States to know their low density lipoprotein cholesterol (referred to in this resolution as “LDL-C”) number;
(2) designates September 2025 as “National Cholesterol Education Month”;
(3) designates September 30, 2025, as “LDL-C Awareness Day”; and
(4) recognizes the urgent need for screening and treating of elevated LDL-C to reduce the risk of cardiovascular disease and cardiovascular events, including heart attacks and strokes. <all>
Comments